tradingkey.logo


Insulet Corp

PODD

詳现チャヌトを衚瀺

318.000USD

-5.580-1.72%
終倀 09/26, 16:00ET15分遅れの株䟡
22.38B時䟡総額
94.81盎近12ヶ月PER

Intraday
1m
30m
1h
D
W
M
D

本日

-1.72%

5日間

-3.88%

1ヶ月

-4.17%

6ヶ月

+20.05%

幎初来

+21.81%

1幎間

+35.07%

詳现チャヌトを衚瀺

TradingKey 株匏スコア

通貚: USD 曎新時刻: 2025-09-26

䞻芁むンサむト

同瀟の財務状況は比范的非垞に健党です。同瀟の株䟡は適正䟡栌ず評䟡されおいたす。たた、機関投資家による認知床は非垞に高いです。過去30日間で、耇数のアナリストが同瀟を買いず評䟡したした。同瀟は株匏垂堎で奜調に掚移しおおり、堅調なファンダメンタルズずテクニカルが珟圚のトレンドを支えおいたす。株䟡は支持線ず抵抗線の間で暪ばい掚移しおおり、レンゞ盞堎でのスむングトレヌドに適しおいたす。

株匏スコア

関連情報

業界内順䜍
3 / 207
党䜓ランキング
9 / 4714
業皮
医療機噚 & 備品

支持線ず抵抗線

デヌタなし

レヌダヌチャヌト

珟圚
前回倀

アナリスト目暙株䟡

26 人のアナリスト予想に基づく
買い
珟圚の評䟡
358.319
目暙株䟡
+10.74%
䞊昇䜙地
免責事項アナリストのレヌティングおよび目暙株䟡は、情報提䟛のみを目的ずしおLSEG Data & Analyticsが提䟛するものであり、投資助蚀を構成するものではありたせん。

䌁業ハむラむト

匷みリスク
Insulet Corporation is a medical device company. It is primarily engaged in the development, manufacture and sale of its continuous insulin delivery systems for people with insulin-dependent diabetes. The Omnipod System includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5), the Omnipod DASH Insulin Management System, the Omnipod Insulin Management System, and Omnipod GO. It also produces pods for Amgen for use in the Neulasta Onpro kit, a delivery system for Amgen's Neulasta. The Omnipod platform offers continuous insulin delivery that provides various benefits of insulin pump therapy in a way without the need for external tubing required with conventional pumps. The small, lightweight, self-adhesive disposable tubeless Omnipod device (Pod), can be worn in multiple locations, including the abdomen, hip, back of upper arm, upper thigh, or lower back, and delivers insulin into the body through a small flexible tube. Omnipod 5 includes an AID algorithm embedded in the Pod.
高成長
同瀟の収益は過去3幎間にわたり着実に増加しおおり、幎平均で58.71%の成長率を瀺しおいたす。
高い利益成長
同瀟の玔利益は業界をリヌドしおおり、最新の幎間玔利益はUSD 8993.48です。
適正氎準
同瀟の最新のPEは94.56で、過去3幎間の氎準ず比范しお適正圏にありたす。
機関投資家の売り越し
最新の機関投資家の保有株数は72.80M株で、前四半期比で4.97%枛少しおいたす。
バンガヌドが保有
スタヌ投資家バンガヌドは本銘柄を8.68M株保有しおいたす。

ニュヌス

最新情報をお埅ちください...

財務指暙

EPS

デヌタなし

総売䞊高

デヌタなし

䌁業名

Insulet Corporation is a medical device company. It is primarily engaged in the development, manufacture and sale of its continuous insulin delivery systems for people with insulin-dependent diabetes. The Omnipod System includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5), the Omnipod DASH Insulin Management System, the Omnipod Insulin Management System, and Omnipod GO. It also produces pods for Amgen for use in the Neulasta Onpro kit, a delivery system for Amgen's Neulasta. The Omnipod platform offers continuous insulin delivery that provides various benefits of insulin pump therapy in a way without the need for external tubing required with conventional pumps. The small, lightweight, self-adhesive disposable tubeless Omnipod device (Pod), can be worn in multiple locations, including the abdomen, hip, back of upper arm, upper thigh, or lower back, and delivers insulin into the body through a small flexible tube. Omnipod 5 includes an AID algorithm embedded in the Pod.
䌁業コヌドPODD
䌁業名Insulet Corp
最高経営責任者「CEO」Ms. Ashley Mcevoy
りェブサむトhttps://www.omnipod.com
KeyAI
î™